Type to search

Biomunex Unveils MAIT Cell Redirection Approach for Lead Immuno-oncology Program at PEGS Boston Conference | Pharmtech Focus
Biomunex Appoints Dr. Simon Plyte, PhD, as Chief Scientific Officer | Pharmtech Focus
Biomunex Pharmaceuticals’ Breakthrough Immunotherapy Project Receives Grants Close to €3 Million | Pharmtech Focus